These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
726 related articles for article (PubMed ID: 33285051)
21. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis. Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF; Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359 [TBL] [Abstract][Full Text] [Related]
22. Radiomic biomarkers for platinum-refractory head and neck cancer in the era of immunotherapy. Lu HJ; Shen CY; Chiu YW; Lin WL; Peng CY; Tseng HC; Hsin CH; Chuang CY; Chen CC; Wu MF; Huang WS; Shen WC Oral Dis; 2024 Oct; 30(7):4220-4230. PubMed ID: 38178608 [TBL] [Abstract][Full Text] [Related]
23. Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Wada A; Enokida T; Okano S; Sato M; Tanaka H; Ueda Y; Fujisawa T; Takeshita N; Tanaka N; Tahara M Eur J Cancer; 2023 May; 184():30-38. PubMed ID: 36898232 [TBL] [Abstract][Full Text] [Related]
24. Emerging immune checkpoint inhibitors for the treatment of head and neck cancers. Green SE; McCusker MG; Mehra R Expert Opin Emerg Drugs; 2020 Dec; 25(4):501-514. PubMed ID: 33196319 [No Abstract] [Full Text] [Related]
25. Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study. Pontes F; Garcia AR; Domingues I; João Sousa M; Felix R; Amorim C; Salgueiro F; Mariano M; Teixeira M Cancer Treat Res Commun; 2021; 27():100375. PubMed ID: 33882378 [TBL] [Abstract][Full Text] [Related]
26. Neutrophil-to-lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta-analysis. Takenaka Y; Oya R; Takemoto N; Inohara H Head Neck; 2022 May; 44(5):1237-1245. PubMed ID: 35146824 [TBL] [Abstract][Full Text] [Related]
27. Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME. Chevalier T; Daste A; Saada-Bouzid E; Loundou A; Peyraud F; Lambert T; Le Tourneau C; Peyrade F; Dupuis C; Alfonsi M; Fayette J; Reure J; Huguet F; Fakhry N; Toullec C; Salas S Cancer Med; 2021 Jun; 10(12):3952-3963. PubMed ID: 34080776 [TBL] [Abstract][Full Text] [Related]
28. PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer. Ito T; Okamoto I; Tokashiki K; Sato H; Okada T; Yamashita G; Nagao T; Hirai H; Saigusa N; Tsukahara K Anticancer Res; 2022 Mar; 42(3):1547-1554. PubMed ID: 35220251 [TBL] [Abstract][Full Text] [Related]
29. Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Suzuki S; Toyoma S; Kawasaki Y; Koizumi K; Iikawa N; Shiina K; Endo T; Abe T; Kouga T; Yamada T Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833369 [No Abstract] [Full Text] [Related]
30. Overall Survival, Treatment Duration, and Rechallenge Outcomes With ICI Therapy for Recurrent or Metastatic HNSCC. Sun L; Cohen RB; D'Avella CA; Singh AP; Schoenfeld JD; Hanna GJ JAMA Netw Open; 2024 Aug; 7(8):e2428526. PubMed ID: 39158913 [TBL] [Abstract][Full Text] [Related]
31. The predictive and prognostic value of weight loss and body composition prior to and during immune checkpoint inhibition in recurrent or metastatic head and neck cancer patients. Willemsen ACH; De Moor N; Van Dessel J; Baijens LWJ; Bila M; Hauben E; van den Hout MFCM; Vander Poorten V; Hoeben A; Clement PM; Schols AMWJ Cancer Med; 2023 Apr; 12(7):7699-7712. PubMed ID: 36484469 [TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis of randomized clinical trials. Dang S; Zhang S; Zhao J; Li X; Li W Cancer Med; 2023 Oct; 12(20):20277-20286. PubMed ID: 37814950 [TBL] [Abstract][Full Text] [Related]
33. Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial. Guo Y; Ahn MJ; Chan A; Wang CH; Kang JH; Kim SB; Bello M; Arora RS; Zhang Q; He X; Li P; Dechaphunkul A; Kumar V; Kamble K; Li W; Kandil A; Cohen EEW; Geng Y; Zografos E; Tang PZ Ann Oncol; 2019 Nov; 30(11):1831-1839. PubMed ID: 31501887 [TBL] [Abstract][Full Text] [Related]
34. Paclitaxel-Ifosfamide-based Therapy as Salvage Treatment in Platinum-resistant Recurrent/Metastatic Head and Neck Cancer. Chou MY; Wu WC; Chu PY; Tai SK; Chang PM; Lee TL; Chen TH; Yang MH In Vivo; 2024; 38(4):1891-1899. PubMed ID: 38936932 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck. Saleh K; Auperin A; Martin N; Borcoman E; Torossian N; Iacob M; Ferrand FR; Khalife N; Baste N; Guigay J; Le Tourneau C; Daste A; Saada-Bouzid E; Even C Eur J Cancer; 2021 Nov; 157():190-197. PubMed ID: 34536943 [TBL] [Abstract][Full Text] [Related]
36. Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis. Saba NF; Chaudhary R; Kirtane K; Marra A; Ekpenyong A; McCook-Veal A; Schmitt NC; Gross JH; Patel MR; Remick J; Bates JE; McDonald MW; Rudra SF; Stokes WA; Biernacki M; Song X; Slebos RJC; Liu Y; Steuer CE; Shin DM; Teng Y; Chung CH Clin Cancer Res; 2024 Oct; 30(20):4601-4608. PubMed ID: 39167623 [TBL] [Abstract][Full Text] [Related]
37. Outcomes Among Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Checkpoint Inhibitors. Hobday SB; Brody RM; Kriegsman B; Basu D; Newman J; Cohen RB; Lukens JN; Singh A; D'Avella CA; Sun L JAMA Otolaryngol Head Neck Surg; 2022 Oct; 148(10):918-926. PubMed ID: 35980666 [TBL] [Abstract][Full Text] [Related]
38. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials. Poulose JV; Kainickal CT World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989 [TBL] [Abstract][Full Text] [Related]
39. Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab. Economopoulou P; Kotsantis I; Papaxoinis G; Gavrielatou N; Anastasiou M; Pantazopoulos A; Kavourakis G; Gkolfinopoulos S; Panayiotides I; Delides A; Psyrri A Oral Oncol; 2020 Dec; 111():105013. PubMed ID: 32977184 [TBL] [Abstract][Full Text] [Related]
40. Prognostic factors and risk-stratification model of recurrent or metastatic head and neck squamous cell carcinoma treated with cetuximab containing regimen. Yang MH; Chen TH; Wang HM; Hsieh JC; Huang HC; Hsieh MC; Yen CJ; Wu SY; Hua CH; Lien MY; Chang YF; Wang HC; Chien CY; Huang TL; Lu HJ; Lin JC; Wang CC; Liu YC; Chen JP; Lu WC; Yiu CY; Lin CL; Lou PJ; Chu PY BMC Cancer; 2024 Oct; 24(1):1227. PubMed ID: 39369189 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]